Skip to content

JD Pharma

Active Private limited companyfounded 2015active for 11 yearsOverleiestraat 52, 8500 KortrijkKBO/BCE: BE 0639.894.746

Annual accounts 2025

micro format, filed on 28-08-2026, 28 days late
€514,700
▲ 10.4%
€1.6m
▲ 18.9%
€48,565
▼ 18.8%
31.2%
▼ 2.4 percentage points
9.4%
▼ 3.4 percentage points
2.9%
▼ 1.4 percentage points

Turnover is estimated at about €210,000, probably between €180,000 and €260,000. The micro format does not state turnover.

Balance sheet

balance sheet total €1.6m on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

31.2%

Higher than 34% of the 10,290 companies filing micro accounts in financial services (NACE 64) in 2025.

2.9%

Higher than 31% of the 10,140 companies filing micro accounts in financial services (NACE 64) in 2025.

JD Pharma Middle half of the sector 80% of the sector Micro accounts in financial services (NACE 64)

Net result: middle half · Equity: top quarter · Balance sheet total: top quarter

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202220212020201920182017201615 months
230,19610,777352,891950,79701,765175,9330019,274
13,650-1,047-30,603-29,75714,59742,553-58,44923,85934,592-
31.2%33.6%28.9%16.3%58.1%50.5%37.4%66.8%57.4%37.7%
9.4%12.8%54.5%18.1%25.1%26.7%28.3%33.7%60.7%61.7%
2.9%4.3%15.7%3.0%14.6%13.5%10.6%22.5%34.9%23.3%

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202220212020201920182017201615 months
Balance sheet: assets
20/58 1.6m1.4m1.4m1.1m260,796224,561222,00393,11671,84842,974
20 -------0--
21/28 1.5m1.4m1.4m1.1m140,216152,880166,5136,74610,60114,456
21 -------0--
22/27 587,347411,417427,982127,551140,216152,880166,5136,74610,60114,456
22 570,944397,303422,318125,187135,998146,810157,6220--
23 9,7845,7785,1531,5003,0004,5006,0000--
24 6,6198,3375118641,2171,5712,8916,74610,60114,456
26 -------0--
27 -------0--
28 950,797950,797950,797950,797---0--
29/58 109,52723,83929,65657,773120,58171,68055,49186,37161,24828,518
29 -------0--
290 -------0--
291 -------0--
3 -------0--
30/36 -------0--
37 -------0--
40/41 80,6099,41311,61610,99944,1049,81736,5168,6708,49510,357
40 77,5489,41311,61610,99943,6409,81710,9778,6708,49510,357
41 3,061--0464025,5390--
50/53 -------0--
54/58 27,50613,85614,90445,50675,26360,66618,11376,56252,70318,111
490/1 1,4115703,1361,2681,2131,1978621,1385050
Balance sheet: equity and liabilities
10/49 1.6m1.4m1.4m1.1m260,796224,561222,00393,11671,84842,974
10/15 514,700466,135406,361185,075151,518113,48783,13462,23441,26816,201
10/11 18,60018,60018,60018,60018,60018,60018,6006,2006,2006,200
100 ------18,60018,60018,60018,600
101 ------012,40012,40012,400
11 -------0--
1100/10 -------0--
12 -------0--
13 496,100447,535387,761166,475132,91894,88764,53456,03435,06810,001
130/1 --01,8601,8601,860-0--
130 ------1,8601,8601,753500
1311 --01,8601,8601,860----
1312 -------0--
1319 -------0--
132 -------0--
133 496,100447,535387,761164,615131,05893,02762,67454,17433,3149,501
14 -------0--
15 -------0--
19 -------0--
16 -------0--
160/5 -------0--
160 -------0--
161 -------0--
162 -------0--
163 -------0--
164/5 -------0--
168 -------0--
17/49 1.1m919,9191.0m951,046109,278111,074138,86930,88330,58126,773
17 410,237288,736308,57079,44586,77894,111101,44403,7278,134
170/4 410,237288,736308,57079,44586,77894,111101,44403,7278,134
175 -------0--
176 -------0--
178/9 -------0--
42/48 721,997630,315685,977867,11922,50116,96337,14630,72426,85318,639
42 35,22219,83319,8337,3337,3337,3337,3333,7274,4074,336
43 -------0--
430/8 -------0--
439 -------0--
44 71,5032,1556,0363952,7033182,7041,851438418
440/4 71,5032,1556,0363952,7033182,7041,851438418
441 -------0--
46 -------0--
45 11,71012,13611,34712,26612,4658,54712,10919,10813,4427,728
450/3 9,91310,3399,55010,47010,6686,75010,35917,35811,8426,228
454/9 1,7971,7971,7971,7971,7971,7971,7501,7501,6001,500
47/48 603,562596,191648,760847,125076415,0006,0378,5666,156
492/3 7388677,5284,482-0279159--
Income statement
76A -07,800----0--
9900 136,528123,339359,90167,42263,90556,65748,99132,72039,80320,261
62 -------0--
630 54,26626,83152,46012,66512,66515,39816,1663,8553,8555,742
631/4 -------0--
635/8 -------0--
640/8 6,7704,3062,7091,7621,7261,7151,817982517550
649 -------0--
66A 0511-053-0199174-
9901 75,49391,690304,73252,99549,46139,54431,00827,68435,25813,969
75/76B 01--010000401-
75 01--010000401-
76B -------0--
65/66B 9,9889,3159,1417,0001,1351,015844715268285
65 9,9889,3159,1417,0001,1351,015844715268285
66B -------0--
9903 65,50582,377295,59145,99548,32638,62830,16426,96935,39013,684
67/77 16,93922,60374,30512,43810,2958,2766,6636,00310,3243,683
9904 48,56559,774221,28633,55738,03130,35323,50120,96625,06710,001
789 -------0--
689 -------0--
9905 48,56559,774221,28633,55738,03130,35323,50120,96625,06710,001
Appropriation of the result
9906 48,56559,774221,28633,55738,03130,35323,50120,96625,06710,001
791/2 -------0--
691/2 48,56559,774221,28633,55738,03130,3538,50120,96625,06710,001
691 -------0--
6920 ------01071,253500
6921 48,56559,774221,28633,55738,03130,3538,50120,85923,8139,501
694/7 -----015,0000--
694 -----015,0000--
695 -------0--
696 -------0--
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The full notes are in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 28-08-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank

The accounts were filed on 28-08-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00440218.

Financial year Type Filed Reference Document
31-12-2025 micro format 28-08-2026 2026-00440218 PDF
31-12-2024 micro format 24-07-2025 2025-00306295 PDF
31-12-2023 micro format 19-07-2024 2024-00261257 PDF
31-12-2022 micro format 12-07-2023 2023-00226908 PDF
31-12-2021 micro format 31-08-2022 2022-20358495 PDF
31-12-2020 micro format 08-07-2021 2021-32300166 PDF
31-12-2019 micro format 25-08-2020 2020-43800111 PDF
31-12-2018 micro format 11-07-2019 2019-31000437 PDF
31-12-2017 abbreviated format 29-08-2018 2018-51700074 PDF
31-12-2016 abbreviated format 28-08-2017 2017-47900297 PDF

Securities and guarantees

on own assets and for others
Item20252024202320222021
Mortgages, amount registered€50,000€50,000€50,000€25,000€25,000
€470,000€310,000€310,000€85,000€85,000
Carrying value of the mortgaged assets€334,438€358,572€382,481€125,187€135,998

Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€230,196€10,777€352,891--
Financial fixed assets---€950,797-
€54,266€26,831€52,460€12,665€12,665

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on JD Pharma

The operating result for 2025 is 18% lower than in 2024 and the lowest since 2022. It is the second fall in a row.

Debt's share of the balance-sheet total rises from 66.4% to 68.8%. Equity and debt are higher.

Next steps